R916562

Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage:	HY-104075 1037798-41-6 C ₂₆ H ₃₀ ClN ₉ S 536.09 TAM Receptor; VEGFR Protein Tyrosine Kinase/RTK Please store the product under the recommended conditions in the Certificate of	$ \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} $ } \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} } \\ \end{array} \\ \end{array} \\ } \\ \end{array} \\ } \\ \end{array} \\ } \\ } \\
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	

BIOLOGICAL ACTIVITY				
BIOLOGICAL ACTIVITY				
Description	R916562 is an orally active and selective Axl/VEGF-R2 inhibitor with IC ₅₀ s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis ^[1] .			
IC ₅₀ & Target	Axl 136 nM (IC ₅₀)	VEGF-R2 24 nM (IC ₅₀)		
In Vivo	R916562 treatment at 85 mg/kg or 125 mg/kg orally b.i. d for 21 days results in statistically significant tumor growth inhibitions of 69% or 83% respectively. R916562 shows 73% reduction in fibroblast growth factor-induced neovascularization in a mouse corneal micropocket assay at a dose of 100 mg/kg and 50% reduction at 50 mg/kg ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

PROTOCOL	
Animal Administration ^[1]	Mice ^[1] The nu/nu mice are used in the study. In the MDA-MB-231 human breast cancer xenograft model, mice are given 125 mg/kg b.i.d. orally for 21 days. Mean tumor volume is measured ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Goff D, et al. Discovery of dual Axl/VEGF-R2 inhibitors as potential anti-angiogenic and anti-metastatic drugs for cancer chemotherapy. Bioorg Med Chem Lett. 2017 Aug 15; 27(16):3766-3771.

Product Data Sheet



Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA